REGENXBIO RGNX 深 沪
等待开盘 10-09 09:30:00 美东时间
12.22
+1.710
+16.27%
华盛通- 最 高12.30
- 今 开10.53
- 成交量 97.31万股
- 最 低 10.52
- 昨 收 10.51
- 总市值 6.17亿
- 52周最高 12.30
- 市盈率 静 --
- 换手率 1.93%
- 52周最低 5.035
- 委 比 -66.44%
- 总股本 5051.42万
- 历史最高 85.10
- 量 比 1.53
- 振 幅 16.94%
- 历史最低 5.035
- 每 手 1
- 风险率 3.59%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多美股大行评级 | 最高300美元，AMD获多家大行上调目标价！
今日重点评级关注：Maxim Group：维持Gain Therapeutics"买入"评级，目标价从5美元升至7美元；HC Wainwright & Co.：维持Icecure Medical"买入"评级，目标价从2美元升至2.5美元
10-08 09:14
The Analyst Verdict: Regenxbio In The Eyes Of 7 Experts
Throughout the last three months, 7 analysts have evaluated Regenxbio (NASDAQ:R...
10-08 04:01
7 Analysts Assess Regenxbio: What You Need To Know
Throughout the last three months, 7 analysts have evaluated Regenxbio (NASDAQ:R...
10-07 21:04
HC Wainwright & Co. Reiterates Buy on Regenxbio, Maintains $34 Price Target
HC Wainwright & Co. analyst Yi Chen reiterates Regenxbio (NASDAQ:RGNX) with a Buy and maintains $34 price target.
10-07 18:15
REGENXBIO To Present RGX-202 Phase I/II Functional Data At WMS 2025; Highlights NSAA Gains, Favorable Safety Profile Vs. Natural History Controls
REGENXBIO Inc. (NASDAQ: RGNX) today announced Chief Medical Officer, Steve Pakola, M.D., will present at the International Congress of the World Muscle Society taking place in Vienna, Austria, October 7-11, 2025.
09-29 19:18
REGENXBIO Announces Presentation at the World Muscle Society
ROCKVILLE, Md., Sept. 29, 2025 /PRNewswire/ -- REGENXBIO Inc. (Nasdaq: RGNX) today announced Chief Medical Officer, Steve Pakola, M.D., will present at the International Congress of the Worl...
09-29 19:05
REGENXBIO reports positive data from Hunter syndrome
REGENXBIO (NASDAQ:RGNX) reported positive results from its trial investigating the gene therapy, clemidsogene lanparvovec (RGX-121), for Hunter syndrome treatment. In the 12-month pivotal trial involv...
09-05 21:42
REGENXBIO Announces Data From Phase I/II/III CAMPSIITE Trial Of Clemidsogene Lanparvovec For Treatment Of Patients With Mucopolysaccharidosis Type II At ICIEM 2025
12-month pivotal data further demonstrate the ability of one-time RGX-121 treatment to improve outcomes for patients with MPS II>80% reduction in CSF levels of HS D2S6, key biomarker of MPS II brain disease, sustained
09-05 19:08
Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
Ultragenyx Pharmaceutical Inc. has granted 113,572 restricted stock units to 33 newly hired non-executive officers under the Ultragenyx Employment Inducement Plan, with a grant date of August 16, 2025. The awards, approved by the company's compensation committee, vest over four years, with 25% of shares vesting annually contingent on continuous employment. Ultragenyx, a biopharmaceutical company focused on developing therapies for rare and ultra-...
08-21 21:00
Analyst Expectations For Regenxbio's Future
Across the recent three months, 5 analysts have shared their insights on Regenx...
08-19 20:00
